相关实验视频
Updated: May 22, 2025

10:20
In vitro Measurements of Tracheal Constriction Using Mice
Published on: June 25, 2012
20.7K
探索呼吸道二基酸酶1在阻塞性呼吸道疾病中的作用
Naoya Tanabe1,2, Hisako Matsumoto1,3,2, Mariko Kogo1,2
1Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
ERJ open research
|May 20, 2025
概括
在阻塞性呼吸道疾病中,高滴基酶1 (DPP1) 水平可能会减少粘液堵塞,但会增加呼吸道损伤,可能导致呼吸道扩张. 这表明DPP1在COPD和喘等疾病中影响炎症和呼吸道结构.
科学领域:
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 众所周知,二乙酶1 (DPP1) 在支气管炎症中恶化了中性友好性炎症.
- DPP1在COPD,喘和喘-COPD重叠 (ACO) 等阻塞性呼吸道疾病中的作用尚不清楚.
- 这项研究调查了DPP1在这些条件下对炎症,粘液堵塞,呼吸道扩张和微生物群的影响.
研究的目的:
- 为了测试空气道DPP1增强中性友炎症的假设.
- 评估DPP1对粘液堵塞,呼吸道扩张和呼吸道微生物群的影响.
- 探索DPP1在COPD,喘和ACO中的病原遗传作用.
主要方法:
- 唾液DPP1,细胞差异和COPD,喘和ACO患者的微生物组的横截面评估.
- 测量唾液高流动性组框1 (HMGB1) 来评估气道上皮损伤.
- 胸部CT扫描以评估粘液塞,气道扩张 (Reiff分数) 和气道壁尺寸.
主要成果:
- 患者被分为高DPP1/高中性粒细胞,低DPP1/高中性粒细胞和低中性粒细胞类别.
- 高DPP1/高中性粒细胞组显示粘液堵塞减少,Firmicutes的相对丰度较低.
- 此组还表现出更高的唾液HMGB1水平和没有粘液堵塞的气道扩张的流行 (29%).
结论:
- 高液DPP1水平可能会降低Firmicutes殖民和粘液堵塞.
- 较高的DPP1似乎会增加气道上皮损伤.
- 这种损伤可能导致气道扩张,而不依赖于粘液堵塞,导致中性恋阻塞性气道疾病.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
329
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
329
Peptic Ulcer Disease I: Introduction
114
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
114
Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K

